Kos Pharmaceuticals, Inc (KOSP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	5/5/2005 9:46:35 AM
	of 118

Merrill: Price Objective Changes Kos Pharmaceuticals Inc (KOSP, $54.29, C-1-9) Reiterate Buy. Q1 Conf Call: Raising PT from $60 to $66. Raising 05E from $2.55 to $2.65 and 06E from $3.06 to $3.15. KOSP believes that the newly acquired hypertension products Cardizem LA, Teveten, and Teveten HCT will have synergistic effects on its sales force productivity. Filed an sNDA for its modified formulation of Niaspan in May, & sees a 6 mo review. Expects 2Q rev to be about $170M, & EPS to be just below Q1 EPS of $0.58. Despite the big run that KOSP has had, we believe that growth of the Niaspan franchise & EPS accretion from the deal should drive KOSP higher over the next year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next